ANGIOPREDICT - an FP7-funded project enabling personalised medicine for patients with metastatic colorectal cancer.

Study

Study ID	Alternative Stable ID	Type
EGAS00001005423		Other

Study Description

In ANGIOPREDICT, academic cancer biologists and industry-based biotechnology researchers will work together with clinicians to identify biomarkers to predict whether individual metastatic colorectal cancer patients will respond positively to Avastin® combination therapy. Diagnostic tests using these biomarkers will also be developed to provide clinicians with the means to predict patient treatment responses in the future.

Study Datasets 1 dataset.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001008463	Exome (_{N,T}{1,2}) RNAseq (polyA - _PolyA, and RiboZero - _RibZ) Methylation (SeqCapEpi - MAPD). Exome (_{N,T}{1,2}) RNAseq (polyA - _PolyA, and RiboZero - _RibZ) Methylation (SeqCapEpi - MAPD).	Illumina HiSeq 2500	1

Who archives the data?

Publications

Citations

Retrieving...